News

Does the 23andMe Acquisition Make Regeneron a Buy Now?
Regeneron (NASDAQ: REGN) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its previous ...
The Hudson Independent2d
Regeneron Enters into Agreement to Acquire Consumer Genetics Business
Tarrytown-based Regeneron Pharmaceuticals, Inc. has announced it has been named the successful bidder in the bankruptcy ...
Regeneron to buy 23andMe out of bankruptcy for $256 million
Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's ...
Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data
Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...
MassDevice4d
Regeneron to acquire 23andMe for $256M, plans to continue consumer genetics services
Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...
Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the ...
Explore more
Zacks Investment Research on MSN22h
Regeneron Initial Data on Multiple Myeloma Drug Encouraging
Regeneron Pharmaceuticals, Inc. REGN announced encouraging initial results from two cohorts of the early-stage study on ...
Pharmabiz9h
Predictive Oncology breakthrough coincides with Regeneron Pharma’s acquisition of 23andMe for $256 million: Artificial intelligence meets genomics
Pittsburgh, Pennsylvania Saturday, May 24, 2025, 15:00 Hrs [IST] ...